UA84402C2 - Применение монооксида углерода для лечения воспаления почек - Google Patents

Применение монооксида углерода для лечения воспаления почек

Info

Publication number
UA84402C2
UA84402C2 UA20041210106A UA20041210106A UA84402C2 UA 84402 C2 UA84402 C2 UA 84402C2 UA 20041210106 A UA20041210106 A UA 20041210106A UA 20041210106 A UA20041210106 A UA 20041210106A UA 84402 C2 UA84402 C2 UA 84402C2
Authority
UA
Ukraine
Prior art keywords
carbon monoxide
nephritis
treatment
biomarker
spleen
Prior art date
Application number
UA20041210106A
Other languages
English (en)
Ukrainian (uk)
Inventor
Августин М.К. Чой
Лео Е. Оттербейн
Original Assignee
Йельский Университет
Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йельский Университет, Джонс Хопкинс Юниверсити filed Critical Йельский Университет
Publication of UA84402C2 publication Critical patent/UA84402C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Данное изобретение относится к медицине и касается применения газообразного монооксида углерода для изготовления лекарственного средства при лечении пациента, который страдает от или склонен к риску возникновения локализованного воспаления почек.
UA20041210106A 2002-05-09 2002-05-09 Применение монооксида углерода для лечения воспаления почек UA84402C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (1)

Publication Number Publication Date
UA84402C2 true UA84402C2 (ru) 2008-10-27

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041210106A UA84402C2 (ru) 2002-05-09 2002-05-09 Применение монооксида углерода для лечения воспаления почек

Country Status (13)

Country Link
EP (1) EP1501523A4 (ru)
JP (1) JP2005532314A (ru)
KR (1) KR20040106515A (ru)
CN (1) CN1638781A (ru)
AU (1) AU2002308676B2 (ru)
BR (1) BR0215717A (ru)
CA (1) CA2484770A1 (ru)
EA (1) EA200401478A1 (ru)
MX (1) MXPA04011113A (ru)
NO (1) NO20044865L (ru)
RS (1) RS96904A (ru)
UA (1) UA84402C2 (ru)
WO (1) WO2003094932A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2042181A1 (en) 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
HRP20040972A2 (en) 2002-04-15 2005-06-30 University Of Pittsburgh Of The Commonwealth Systeyale University Methods of treating ileus
AU2003223562B2 (en) 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
DK1505990T3 (da) * 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
EP2099439A2 (en) * 2006-12-06 2009-09-16 Alfama - Investigação E Desenvolvimento De Produto Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
WO2012096912A1 (en) * 2011-01-14 2012-07-19 Children's Hospital Los Angeles Solution of carbon monoxide for treatment of disease, including sickle cell disease
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9365419B2 (en) 2011-03-24 2016-06-14 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring alzheimer's disease
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US10031126B2 (en) 2013-04-04 2018-07-24 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
WO2019235165A1 (ja) 2018-06-08 2019-12-12 住友精化株式会社 炎症性消化器官疾患用組成物
JP7396598B2 (ja) * 2018-06-08 2023-12-12 住友精化株式会社 皮膚創傷用組成物
US12370210B2 (en) * 2019-06-06 2025-07-29 The General Hospital Corporation Carbon monoxide as a treatment for neurodegenerative disease
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
ES2210585T3 (es) * 1996-08-27 2004-07-01 Messer Griesheim Gmbh Medicamento que contiene hidrogeno.
JP2004526739A (ja) * 2001-03-30 2004-09-02 サングスタット メディカル コーポレイション 血管の、炎症性の及び免疫の障害の治療のための、一酸化炭素生成性化合物

Also Published As

Publication number Publication date
AU2002308676A1 (en) 2003-11-11
EP1501523A1 (en) 2005-02-02
JP2005532314A (ja) 2005-10-27
WO2003094932A1 (en) 2003-11-20
MXPA04011113A (es) 2005-02-14
RS96904A (sr) 2007-02-05
KR20040106515A (ko) 2004-12-17
CN1638781A (zh) 2005-07-13
AU2002308676B2 (en) 2009-06-11
CA2484770A1 (en) 2003-11-20
BR0215717A (pt) 2005-02-22
EA200401478A1 (ru) 2005-12-29
EP1501523A4 (en) 2006-12-13
NO20044865L (no) 2004-12-07

Similar Documents

Publication Publication Date Title
EP2228654A3 (en) Diagnosis and prevention of cancer cell invasion
WO2004078124A3 (en) Methods and compositions involving mda-7
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
PL1656346T3 (pl) 1,2,3,4-Tetrapodstawiony indol do leczenia chorób dróg oddechowych
UA85559C2 (en) Aminobenzophenone compounds
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2006050389A3 (en) Pyridazine compounds, compositions and methods
NO20076241L (no) Terapier for vaskulaere sykdommer
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
WO2004043341A3 (en) Treatment for hemorrhagic shock
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EP1636160A4 (en) NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
NZ546440A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2007031878A3 (en) Methods of treating nervous disorders
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
GB0522908D0 (en) Therapeutic agents
ZA200604365B (en) Compositions and methods for the diagnosis and treatment of tumor
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen